RT Journal Article
SR Electronic
T1 Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3679
VO 42
IS Suppl 57
A1 Bogdana Basina
A1 Tetyana Pertseva
A1 Lyudmyla Konopkina
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3679.abstract
AB One of the pathogenetic links in COPD is a dysfunction of the RM. RM strength may depend on some medicines.Aim: to determine the effects of BDs on the RM strength in COPD pts during prolonged their admission and during acute test.Materials and methods. We studied 50 COPD pts, divided into two groups depending on the treatment: 1 – 22 male (63,7±1,6yrs) who constantly didn’t use any drug, 2 – 28 male (64,0±1,4yrs), treated though regularly and protractedly (more than 3 yrs), but inadequately according to disease stage (constantly taking only short-acting β2-agonist or combination short-acting β2-agonist/short-acting anticholinergic, but not taking ICS).Measurements included clinical status, spirometry (pre- and post-dose of salbutamol), occlusal spirometry in terms RImax and REmax that described the RM strength during inhalation and exhalation.Results are presented in the Table.View this table:Conclusion: RM strength in pts was lower than in normal; but in those, who regularly and protractedly took short-acting BD it was significantly lower (both in inhalation and exhalation) than in pts who didn’t take regularly any medication. Most likely, it was associated with the need to constantly overcome resistance at current bronchial obstruction. Taking in the acute BD test leads to increased RM strength, possibly by improving contractility of the diaphragm.